 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Compugen, Ltd.
|
-
Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement
(25 Jan 2007)
Medarex, Inc. and Compugen Ltd. have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. Under the terms of the agreement, Medarex and Compugen plan to share discovery, ...
-
Compugen Appoints Eli Zangvil, MD, as Vice President Business Development
(13 Nov 2006)
Compugen Ltd. announced the appointment of Eli Zangvil, MD, as Vice President, Business Development. In this position, Dr. Zangvil will join the Commercial Operations team with management responsibility for selected strategic alliance and business ...
-
Compugen Leads Consortium to Model Cancer Related Kinase Pathway
(10 Mar 2006)
European Commission to Fund SIMAP Consortium
Compugen Ltd. announced that it is leading a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests.The ...
-
Compugen Announces Diagnostic Biomarker Collaboration
(10 Jun 2005)
Compugen Ltd. announced a collaboration agreement with Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, for the development and commercialization of immunoassay diagnostic markers. Under the agreement, Ortho-Clinical Diagnostics and ...
-
Evogene Appoints Ofer Haviv as President and CEO
(01 Jun 2005)
Evogene announced the appointment of Ofer Haviv as President and Chief Executive Officer. Previously, Haviv was the Company's Chief Operating and Financial Officer. Dr Hagai Karchi, who co-founded Evogene in 2002 with Dr Rafi Meissner and has served ...
-
Compugen and Tel Aviv University Announce Unique Predictive Method for Identifying Alternative Splicing in the Human Genome
(28 Oct 2004)
New method does not require EST or microarray data - Hundreds of novel proteins found to date
Compugen Ltd. and Tel Aviv University announced the development of a new method for identifying alternative splicing without the need for either EST (Expressed Sequence Tag) data or microarray experimentation. Hundreds of novel predicted proteins ...
-
Compugen Announces Discovery of Abundant RNA Editing Sites in the Human Transcriptome
(20 Jul 2004)
Findings published in Nature Biotechnology
Tel Aviv, Israel: Compugen Ltd. announced the systematic identification of adenosine to inosine (A to I) RNA editing sites in the human transcriptome, increasing the number of known A to I editing sites from approximately 100 to more than 10,000. ...
-
Compugen Establishes Small Molecule Drug Discovery Subsidiary
(06 Jul 2004)
Compugen Ltd. announced the establishment of a new subsidiary, Keddem Bioscience Ltd., focused on small molecule drug discovery. The program now being transferred to the new company was initiated in 2000 as the chemistry division of Compugen. The ...
|
|
|
|
|
Top
